These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

885 related articles for article (PubMed ID: 30816337)

  • 1. Vessel co-option in cancer.
    Kuczynski EA; Vermeulen PB; Pezzella F; Kerbel RS; Reynolds AR
    Nat Rev Clin Oncol; 2019 Aug; 16(8):469-493. PubMed ID: 30816337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
    Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR
    J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological features of vessel co-option versus sprouting angiogenesis.
    Latacz E; Caspani E; Barnhill R; Lugassy C; Verhoef C; Grünhagen D; Van Laere S; Fernández Moro C; Gerling M; Dirix M; Dirix LY; Vermeulen PB
    Angiogenesis; 2020 Feb; 23(1):43-54. PubMed ID: 31655928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vessel co-option and resistance to anti-angiogenic therapy.
    Kuczynski EA; Reynolds AR
    Angiogenesis; 2020 Feb; 23(1):55-74. PubMed ID: 31865479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
    Donnem T; Hu J; Ferguson M; Adighibe O; Snell C; Harris AL; Gatter KC; Pezzella F
    Cancer Med; 2013 Aug; 2(4):427-36. PubMed ID: 24156015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?
    Coelho AL; Gomes MP; Catarino RJ; Rolfo C; Lopes AM; Medeiros RM; Araújo AM
    Oncotarget; 2017 Jun; 8(24):39795-39804. PubMed ID: 26950275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model.
    Rada M; Lazaris A; Kapelanski-Lamoureux A; Mayer TZ; Metrakos P
    Semin Cancer Biol; 2021 Jun; 71():52-64. PubMed ID: 32920126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-angiogenic tumours and their influence on cancer biology.
    Donnem T; Reynolds AR; Kuczynski EA; Gatter K; Vermeulen PB; Kerbel RS; Harris AL; Pezzella F
    Nat Rev Cancer; 2018 May; 18(5):323-336. PubMed ID: 29520090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of vascularization in murine models of primary and metastatic tumor growth.
    Bugyik E; Renyi-Vamos F; Szabo V; Dezso K; Ecker N; Rokusz A; Nagy P; Dome B; Paku S
    Chin J Cancer; 2016 Feb; 35():19. PubMed ID: 26873579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Models and molecular mechanisms of blood vessel co-option by cancer cells.
    Zhang Y; Wang S; Dudley AC
    Angiogenesis; 2020 Feb; 23(1):17-25. PubMed ID: 31628560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double Immunohistochemical Staining on Formalin-Fixed Paraffin-Embedded Tissue Samples to Study Vascular Co-option.
    Annese T; Errede M; De Giorgis M; Lorusso L; Tamma R; Ribatti D
    Methods Mol Biol; 2023; 2572():101-116. PubMed ID: 36161411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hostile takeover: how tumours hijack pre-existing vascular environments to thrive.
    Winkler F
    J Pathol; 2017 Jul; 242(3):267-272. PubMed ID: 28390068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of tumour vascularization in experimental lung metastases.
    Szabo V; Bugyik E; Dezso K; Ecker N; Nagy P; Timar J; Tovari J; Laszlo V; Bridgeman VL; Wan E; Frentzas S; Vermeulen PB; Reynolds AR; Dome B; Paku S
    J Pathol; 2015 Feb; 235(3):384-96. PubMed ID: 25319725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The vascular network of tumours--what is it not for?
    Sivridis E; Giatromanolaki A; Koukourakis MI
    J Pathol; 2003 Oct; 201(2):173-80. PubMed ID: 14517833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vessel co-option in glioblastoma: emerging insights and opportunities.
    Seano G; Jain RK
    Angiogenesis; 2020 Feb; 23(1):9-16. PubMed ID: 31679081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Inhibition of Vessel Co-Option as an Emerging Strategy for Cancer Therapy.
    Carrera-Aguado I; Marcos-Zazo L; Carrancio-Salán P; Guerra-Paes E; Sánchez-Juanes F; Muñoz-Félix JM
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges.
    Siveen KS; Prabhu K; Krishnankutty R; Kuttikrishnan S; Tsakou M; Alali FQ; Dermime S; Mohammad RM; Uddin S
    Curr Vasc Pharmacol; 2017; 15(4):339-351. PubMed ID: 28056756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different Forms of Tumor Vascularization and Their Clinical Implications Focusing on Vessel Co-option in Colorectal Cancer Liver Metastases.
    Haas G; Fan S; Ghadimi M; De Oliveira T; Conradi LC
    Front Cell Dev Biol; 2021; 9():612774. PubMed ID: 33912554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of the vascular component in growth of solid tumors: a historical review].
    Ribatti D; Vacca A
    Ann Ital Med Int; 1994; 9(2):92-5. PubMed ID: 7522501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor vasculature: a sally port for inhibiting cancer cell spreading.
    Qian CN; Pezzella F
    Cancer Commun (Lond); 2018 Aug; 38(1):52. PubMed ID: 30075743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.